Alembic Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Alembic Pharmaceuticals de 15.7% y 10.4% por año respectivamente. Se prevé que el BPA crezca en un 16% al año. Se espera que la rentabilidad financiera sea de 15.8% en 3 años.

Información clave

16.6%

Tasa de crecimiento de los beneficios

18.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.4%
Tasa de crecimiento de los ingresos	10.7%
Rentabilidad financiera futura	17.4%
Cobertura de analistas	Good
Última actualización	10 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Recent updates

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jan 17

Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

Dec 17

These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Sep 23

Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Sep 02

Here's Why I Think Alembic Pharmaceuticals (NSE:APLLTD) Might Deserve Your Attention Today

Jun 16

Previsiones de crecimiento de beneficios e ingresos

NSEI:APLLTD - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	87,552	11,660	8,820	12,533	4
3/31/2026	77,357	8,640	6,363	9,440	12
3/31/2025	69,708	7,066	4,778	8,224	10
3/31/2024	62,569	6,158	4,757	8,032	N/A
12/31/2023	61,181	5,902	N/A	N/A	N/A
9/30/2023	59,966	5,317	2,042	6,027	N/A
6/30/2023	58,766	5,285	N/A	N/A	N/A
3/31/2023	56,526	3,420	2,805	7,240	N/A
12/31/2022	56,619	2,113	N/A	N/A	N/A
9/30/2022	54,246	2,662	2,893	6,751	N/A
6/30/2022	52,419	3,153	N/A	N/A	N/A
3/31/2022	53,058	5,209	1,267	5,524	N/A
12/31/2021	51,704	7,609	N/A	N/A	N/A
9/30/2021	52,131	8,771	1,767	8,309	N/A
6/30/2021	53,778	10,412	N/A	N/A	N/A
3/31/2021	53,931	11,465	8,039	14,634	N/A
12/31/2020	53,196	11,521	N/A	N/A	N/A
9/30/2020	52,144	10,937	6,209	12,378	N/A
6/30/2020	49,982	10,066	N/A	N/A	N/A
3/31/2020	46,058	8,288	-2,858	4,491	N/A
12/31/2019	43,259	7,282	N/A	N/A	N/A
9/30/2019	41,349	6,638	482	7,967	N/A
6/30/2019	40,211	6,176	N/A	N/A	N/A
3/31/2019	39,347	5,844	476	8,120	N/A
12/31/2018	38,604	5,542	N/A	N/A	N/A
9/30/2018	36,823	5,149	N/A	N/A	N/A
6/30/2018	33,445	4,364	N/A	N/A	N/A
3/31/2018	31,302	4,126	-5,093	3,124	N/A
12/31/2017	29,894	4,119	N/A	N/A	N/A
9/30/2017	29,264	3,678	N/A	N/A	N/A
6/30/2017	30,165	3,661	N/A	N/A	N/A
3/31/2017	31,052	4,032	N/A	3,286	N/A
12/31/2016	30,130	3,999	N/A	N/A	N/A
9/30/2016	31,584	5,828	N/A	N/A	N/A
6/30/2016	32,942	7,515	N/A	N/A	N/A
3/31/2016	31,232	7,200	N/A	9,477	N/A
12/31/2015	30,185	6,986	N/A	N/A	N/A
9/30/2015	26,086	4,998	N/A	N/A	N/A
6/30/2015	21,469	2,881	N/A	N/A	N/A
3/31/2015	20,579	2,829	N/A	1,718	N/A
12/31/2014	20,167	2,739	N/A	N/A	N/A
9/30/2014	19,906	2,692	N/A	N/A	N/A
6/30/2014	19,303	2,535	N/A	N/A	N/A
3/31/2014	18,642	2,355	N/A	2,400	N/A
12/31/2013	17,770	2,179	N/A	N/A	N/A
9/30/2013	16,610	2,002	N/A	N/A	N/A
6/30/2013	15,809	1,811	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (15.7% al año) de APLLTD es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (15.7% al año) de APLLTD crezcan menos que el mercado Indian (17.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de APLLTD crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.4% al año) de APLLTD crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.4% al año) de APLLTD crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de APLLTD sea baja dentro de 3 años (15.8%).

Alembic Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Price target increased by 10% to ₹659

Consensus EPS estimates fall by 19%

Recent updates

Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023)

Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals

Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Consensus EPS estimates fall by 19%

Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022)

Consensus EPS estimates fall by 11%

Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05%

Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w

Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg

Consensus forecasts updated

Insufficient new directors

Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Investor sentiment improved over the past week

Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G

Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration

Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara

Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022

Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg

Consensus EPS estimates fall by 28%

Upcoming dividend of ₹10.00 per share

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Price target decreased to ₹734

First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022)

Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Pirfenidone Tablets

Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Arformoterol Tartrate Inhalation Solution, 15 Mcg (Base)/2 ML Unit-Dose Vial

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Alembic Pharmaceuticals Limited to Report Q4, 2022 Results on May 02, 2022